Cargando…
Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient...
Autores principales: | Smith, Corey, Økern, Grethe, Rehan, Sweera, Beagley, Leone, Lee, Sau K, Aarvak, Tanja, Schjetne, Karoline W, Khanna, Rajiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318490/ https://www.ncbi.nlm.nih.gov/pubmed/25671129 http://dx.doi.org/10.1038/cti.2014.31 |
Ejemplares similares
-
Xeno-free serum replacement for ex vivo culture and expansion of T cells
por: Schjetne, Karoline W, et al.
Publicado: (2014) -
CTS™ immune cell SR for serum free culture and expansion of human T cells
por: Okern, Grethe, et al.
Publicado: (2015) -
T‐cell adoptive immunotherapy for BK nephropathy in renal transplantation
por: Jahan, Sadia, et al.
Publicado: (2020) -
Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation
por: Holmes-Liew, Chien-Li, et al.
Publicado: (2015) -
SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants
por: Panikkar, Archana, et al.
Publicado: (2022)